Hepatic enzymes and immunoinflammatory response to Bio-C Temp bioceramic intracanal medication implanted into the subcutaneous tissue of rats

Camila Soares Lopes1, Mateus Machado Delfino1, Mário Tanomaru-Filho1, Estela Sasso-Cerri2, Juliane Maria Guerreiro-Tanomaru1 & Paulo Sérgio Cerri2

Our purpose was to evaluate the biocompatibility and hepatotoxicity of a new bioceramic intracanal medicament, Bio-C Temp (BIO). The biological properties of BIO were compared with calcium hydroxide-based intracanal medicament (Calen; CAL), used as gold pattern. Polyethylene tubes filled with BIO or CAL, and empty tubes (control group, CG) were implanted into subcutaneous tissue of rats. After 7, 15, 30 and 60 days, the samples were embedded in paraffin for morphological, quantitative and immunohistochemistry analyses. At 7 and 60 days, blood samples were collected for analysis of serum glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels. The data were submitted to two-way ANOVA and Tukey’s test (p ≤ 0.05). No significant difference was detected in serum GOT and GPT levels among BIO, CAL and CG specimens. In all periods, BIO specimens exhibited lower number of inflammatory cells and immunoexpression of IL-6, a pro-inflammatory cytokine, than CAL specimens. The reduction of these parameters was accompanied by significant increase in the collagen content and in the immunoexpression of IL-10, a cytokine involved in the tissue repair, over time. Our findings indicate that Bio-C Temp is biocompatible and had no hepatotoxicity effect.

The complexity of the root canal system can interfere with its complete cleaning and disinfection and even after biomechanical preparation, microorganisms can remain in the root canal system, leading to endodontic treatment failure. Therefore, the use of intracanal medicament may enhance the disinfection of root canal system, apical cementum and dentinal tubules. Moreover, intracanal medication acts as a physical barrier preventing reinfection and reducing the risk of bacteria proliferation.

The calcium hydroxide pastes have been widely used as an intracanal medication acting as a complement to biomechanical preparation due to its antimicrobial potential, ability to dissolve organic tissue, stimulate the osteoblast proliferation, and induction of mineralized tissue formation. Despite these good properties, the calcium hydroxide-based pastes have low radiopacity and flow capacity, which difficult their insertion into the root canal. Moreover, the use of intracanal calcium hydroxide medication for prolonged period, such as for 6 months, induces collagen degradation and, hence, weakening the root dentine and increasing the risk of fracture. Thus, there is the search for new medications or associations with the materials routinely used in order to enhance the properties of the intracanal dressing.

The bioceramic material has been used due to excellent biocompatibility and bioactive potential of the calcium silicate which promotes the deposition of hydroxyapatite on its surface. The bioactivity of bioceramic materials favor osteoblasts survival and differentiation, cells actively involved in the periapical repair enabling the formation of mineralized tissue. Thus, there is currently a growing interest in the development of new materials based on biocompatibility and bioactivity of calcium silicate.
The Angelus (Angelus, Londrina, PR, Brazil) has developed a bioceramic intracanal medication, Bio-C Temp, ready to use. The Bio-C Temp is indicated as an intracanal dressing for endodontic treatment or retreatment, pulpotomy and treatment of immature permanent teeth to induce the apexitization. According to the manufacturer, Bio-C Temp contains calcium silicates associated with calcium tungstate and titanium oxide radiopacifiers, besides calcium aluminates, calcium oxide and base resin.

The Bio-C Temp medication has shown acceptable cell viability when diluted extracts of this medication are added to immortalized fibroblasts culture, human dental pulp cells (hDPcs), and osteoblast-like cells (Saos-2). The cells from Saos-2 co-cultured with Bio-C Temp extracts showed alkaline phosphatase activity and red alizarin-positive mineralized nodules, suggesting that this bioceramic medication exerts an osteogenic activity. The osteogenic activity induced by Bio-C Temp on Saos-2 was similar to that seen in Saos-2 cultures with extracts of calcium hydroxide-based medicaments. Moreover, this bioceramic intracanal medication provides an alkaline pH (pH around 10.79 at 7 days) and releases calcium to the microenvironment, supporting the concept that Bio-C Temp has bioactive potential. Bio-C Temp exhibits greater radiopacity (about 7 mm/Al) than Ultracal XS (Ultradent Products, South Jordan, UT, USA), a calcium hydroxide-based paste.

Despite the physicochemical and in vitro studies, there are no in vivo studies on the biological properties of this material. The implantation of polyethylene tubes filled with endodontic materials into subcutaneous tissues of rats is a method widely used to evaluate the tissue response to the materials as well as the type and extent of the inflammatory reaction. Sections of implants surrounded by connective tissue embedded in paraffin allows us to investigate the complex cascade of cellular and molecular events involved in the tissue response by morphological and immunohistochemical analyses.

This study aimed to evaluate whether Bio-C Temp induces changes in the serum glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) levels and the tissue reaction induced by this bioceramic intracanal medication in the subcutaneous connective tissue in different time points. The biological response induced by Bio-C Temp was compared with a calcium hydroxide-based paste (Calen, SS. White, Rio de Janeiro, RJ, Brazil), used as gold pattern. The null hypothesis was that Bio-C Temp does not present better biological properties when compared with the calcium hydroxide paste.

Results
Serum hepatic enzymes level. As shown in the Fig. 1A,B significant differences in serum GOT and GPT concentrations among BIO, CAL, and CG specimens (p > 0.05) were not observed, at 7 and 60 days. Moreover, from 7 to 60 days, no significant difference was also seen in serum GOT and GPT levels in all groups (p > 0.05).

Morphological findings, capsule thickness and numerical density of number of inflammatory cells. In all groups, well-defined capsules were around the implants (Fig. 2A–L). In BIO and CAL there was an increase in the thickness of the capsules over time. Moreover, material particles were often observed dispersed by the capsules (Fig. 2A,B,D,E,G,H,J,K). At 7 days, necrotic areas were observed in the surface of capsules of BIO and CAL (Fig. 2A,B); in the CAL, necrotic areas were seen at all periods (Fig. 2B,E,H,K,N,O). Necrotic areas were in close juxtaposition to the medications. At initial periods, several inflammatory cells and scarce extracellular matrix components were next to the necrotic areas in BIO (Fig. 2M) and CAL (Fig. 2N) specimens. At 60 days, necrotic areas were seen in the capsules adjacent to the Calen medication (Fig. 2O). The CG specimens were surrounded by thin capsules (Fig. 2C,E,I,L).

According to Fig. 2P, no significant difference was found in the capsule thickness between BIO and CAL specimens at 7 days (p = 0.98). The capsules of BIO specimens were significantly thicker than in CAL (p < 0.0001) at 15, 30 and 60 days. In BIO and CAL specimens, a significant increase in the capsule thickness was verified at 30 days, but a significant reduction was noticed at 60 days (p < 0.0001). At all periods, CG specimens exhibited the lowest values in the capsule thickness and a significant reduction was detected over time (p < 0.0001).

At 7 days, the capsules of all groups contained several inflammatory cells, mainly macrophages and lymphocytes, and few fibroblasts (Fig. 3A–C). However, significant differences were observed among the groups (p < 0.0001); the lowest values of inflammatory cells were obtained in CG capsules while the highest values were found in CAL specimens (Fig. 3A–M). In BIO and CG, a significant reduction in the number of inflammatory cells was observed over time (p < 0.0001). Although the number of inflammatory cells reduced significantly in CAL specimens from 7 to 15 days (p < 0.0001), no significant difference (p = 0.61) was detected between the periods of 15 and 30 days. At 60 days, the number of inflammatory cells in all groups was lower (p < 0.0001) than other time points (Fig. 3M).

Immunohistochemical detection of IL-6. The capsules of all groups showed inflammatory cells, particularly neutrophils and macrophages, containing strong immunolabelling in their cytoplasm (brown-yellow color) in all periods. Moreover, some immunolabelled fibroblasts were also observed (Fig. 4A–L). A reduced immunoexpression was observed in the capsules of CG, particularly at 30 and 60 days (Fig. 4C,F,I,L).

The quantitative analysis (Fig. 4M) revealed that the number of IL-6-immunostained cells decreased significantly from 7 to 60 days (p < 0.0001), in all groups. In all periods, the number of immunolabelled cells was significantly lower around the BIO specimens than in CAL (p < 0.0001) while the lowest values were observed in the capsules of CG.

Immunohistochemical detection of IL-10. In all periods, the immunohistochemistry reaction for detection of IL-10 revealed immunolabelled cells (brown-yellow color) in the capsules of all groups. Although
some inflammatory cells and fibroblasts exhibited immunolabelling for IL-10, strong immunolabelling in the
cytoplasm of mast cells was often seen in the capsules of all groups (Fig. 5A–L).

According to Fig. 5M, the lowest values of IL-10-immunolabelled cells were found in all groups at 7 days.
From 7 to 60 days, the immunoexpression of IL-10 increased significantly in all groups (p < 0.0001). At 7 days,
no significant difference among the groups was detected (p > 0.05). At 15, 30 and 60 days, the number of IL-
10-immunolabelled cells was significantly lower in CG specimens than in BIO and CAL groups (p < 0.0001).
On 15th day, the highest values were found in BIO specimens while, at 30 and 60 days, the highest values were
observed in the CAL specimens (p < 0.0001).

Birefringent collagen content in capsules. At 7 days, all groups exhibited capsules with few and thin
birefringent collagen fibers in yellow/red color (Fig. 6A–C). On 60th day, an evident increase in the birefrin-
gence was observed in the capsules of all groups. In this period, an increase in the bundles of collagen fibers
exhibiting red/orange birefringence was seen in the capsules around all implants (Fig. 6D–F). The quantitative
analysis (Fig. 6G) showed that the amount of birefringent collagen was similar among the groups (p > 0.05) at
7 and 15 days. Although no significant difference between BIO and CAL was found at 30 days, the amount of
birefringent collagen was significantly greater in BIO than CAL specimens at 60 days (p < 0.0001). After 30 and
60 days, the collagen content was significantly greater in CG than in BIO and CAL groups (p < 0.0001). The
analysis revealed a significant increase in the collagen amount in BIO group at 60 days (p < 0.0001). In contrast,
no significant difference was detected in the CAL group over time (p > 0.05). In the CG, the amount of collagen
was significantly greater at 30 and 60 days than in the periods of 7 and 15 days.

Discussion
This is the first study that evaluated the serum GOT and GPT levels and biocompatibility in vivo of Bio-C Temp
bioceramic intracanal medicament after implantation into the subcutaneous tissues of rats. Morphological and
quantitative analyses of capsules around intracanal medications at different time points allow evaluating the
injured tissue as well as the complex cascade of cytokines caused by these medicaments, which may lead to
chronic inflammatory reaction or tissue repair26–28. Furthermore, this methodology allows us to investigate
whether dental materials could promote systemic changes28. The null hypothesis was rejected since Bio-C Temp
favouring the connective tissue repair quickly in comparison with the calcium hydroxide paste.

In the present study, bioceramic medication and calcium hydroxide-based paste did not promote changes in
serum GOT and GPT levels in comparison with CG after 7 and 60 days of implantation. Therefore, the intracanal
Figure 2. (A–L) Light micrographs of sections showing an overview of capsules adjacent to the opening of the implanted tubes (T). In all periods, well-defined capsules (C) are seen. In BIO specimens, several particles (brown/black color) are dispersed throughout the capsules (C). In all periods, thin capsules are observed in the CG. Note necrosis areas (N) in the capsules around Bio-C Temp (A) and Calen paste (B,E,H,K). Bars: 152 µm. (M–O) High magnification of portions of capsules in close juxtaposition to the Bio-C Temp at 7 days (M) and Calen paste at 7 (N) and 60 (O) days; necrosis areas (asterisks) are observed. Arrows, inflammatory cells; Fb, fibroblast; GC, multinucleated giant cell. Bars: 27 µm. HE. (P) The graphic shows the values (expressed as mean ± standard deviation) of capsule thickness (in µm). In each period, the comparison among the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey's test (p ≤ 0.05).
Figure 3. (A–L) Light micrographs showing the innermost portion of capsules. Inflammatory cells (arrows), fibroblasts (Fb), collagen fibers (CF) and material particles (arrowheads) are seen in the capsules. At 15, 30 and 60 days, the capsules of the control group exhibit few inflammatory cells (arrows) and a gradual increase in fibroblasts (Fb) and collagen fibers (CF). BV, blood vessels; HE. Bars: 18 µm. (M) The graphic shows the values (expressed as mean ± standard deviation) of the numerical density of inflammatory cells in the capsules. In each period, the comparison among the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey's test (p ≤ 0.05).
Figure 4. (A–L) Light micrographs showing portions of capsule of sections submitted to immunohistochemistry reaction for detection of IL-6 (brown/yellow color) and counterstained with hematoxylin. In all periods, inflammatory cells with strong immunolabelling in their cytoplasm (arrows) are present in the capsules of all groups. Immunolabelled fibroblasts (Fb) are also observed. BV, blood vessels; material particles (arrowheads). Bars: 18 µm. (M) The graphic shows the values (expressed as mean ± standard deviation) of the numerical density of IL-6-immunolabelled cells in the capsules. In each period, the comparison among the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey's test (p ≤ 0.05).
Figure 5. (A–L) Light micrographs showing portions of capsule of sections submitted to immunohistochemistry for detection of IL-10 (brown/yellow color) and counterstained with hematoxylin. Note that few immunostained cells are present in the capsules of all groups, particularly at 7 days (A–C). In all groups, an evident immunolabelling is present in the mast cells (MC). Arrows, inflammatory cells; BV, blood vessels; material particles, arrowheads. Bars: 18 µm. (M) The graphic shows the values (expressed as mean ± standard deviation) of the numerical density of IL-10-immunolabelled cells in the capsules. In each period, the comparison among the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey’s test (p ≤ 0.05).
Figure 6. (A–F) Light micrographs showing portions of capsule from sections subjected to picrosirius-red and analyzed under polarized illumination. At 7 days, thin birefringent collagen fibers (in red-orange) are dispersed in the capsules. At 60 days, the capsules exhibit thick bundles of birefringent collagen; note an accentuated birefringence in capsules of BIO (D) and CG (F) groups compared to the CAL group (E). Bars: 18 µm. (G) The graphic shows the values (expressed as mean ± standard deviation) of the amount of birefringent collagen (in percentage) in the capsules. In each period, the comparison among the groups is indicated by superscript letters; different letters = significant difference. The superscript numbers indicate the analysis of each group over time; different numbers = significant difference. Tukey’s test (p ≤ 0.05).
medications may not be hepatotoxic, since the measurement in serum of GOT and GPT levels can be used as biochemical parameters of liver function. Usually, hepatic enzymatic changes are associated with structural liver damage. Cellular viability of hDPCs and Saos-2 is directly correlated with the concentration of Bio-C Temp extracts. The cytotoxicity of this bioceramic intracanal medication when added in high concentrations has been associated with the titanium dioxide, which promotes cell damage culminating in cell death by apoptosis. According to the manufacturer, Bio-C Temp also contains base resin in its composition. It is known that resins can release substances, which may promote local and systemic adverse reactions. Here, serum GOT and GPT levels suggest that Bio-C Temp and calcium hydroxide-based pastes may not promote liver injury. However, further studies are needed to evaluate whether these intracanal medications promote structural changes in the liver.

The morphological and quantitative analyses revealed that, in all groups, the greatest values of inflammatory cells were observed at 7 days. The inflammatory reaction induced by empty polyethylene tubes suggests that surgical trauma may stimulate the recruitment of inflammatory cells and, may be responsible, at least the part, for highest numerical density of inflammatory cells initially found, as reported in other studies. However, the number of inflammatory cells in the BIO and CAL specimens was around two folds greater than in CG, which may be attributed to the alkaline pH and chemical composition of these intracanal medications. The Calen paste provides an alkaline pH around 12.4 to microenvironment and, Bio-C Temp provides pH around 10.79 after 7 days. Although calcium hydroxide is not present in the composition of Bio-C Temp, it is known that calcium silicate-based materials react with water raising hydroxyl and calcium ions, resulting in the calcium hydroxide deposition. The alkaline pH induces the recruitment of inflammatory cells to the microenvironment and formation of a coagulation necrosis zone in the tissue surface in contact with the calcium hydroxide-based materials. The necrosis process observed in the initial period in the capsules of CAL and BIO is caused by ions calcium and hydroxyl released by these medications when in contact with tissue fluids. Considering that in CAL specimens, the necrotic areas remained until 60 days and the greatest number of inflammatory cells was observed, it is conceivable to suggest that the release of hydroxyl may be maintained for a long time in the Calen paste. Superficial necrosis areas may be explained due to high pH provided by medications that induces the rupture of cellular membranes and their content leak out, culminating in an inflammatory reaction. However, the cellular damage promoted by these medications may be restricted to tissue area in close juxtaposition to the medication. The alkaline pH promotes vascular proliferation and stimulates the recruitment the macrophages, which migrate to these sites, phagocytizing cell debris and extracellular matrix components. Moreover, superficial necrosis stimulates proliferation and differentiation of mesenchymal cells culminating with collagen formation. Calci-Hand the necrosis process observed in the initial period in the capsules of CAL and BIO is caused by ions calcium and hydroxyl released by these medications when in contact with tissue fluids. Considering that in CAL specimens, the necrotic areas remained until 60 days and the greatest number of inflammatory cells was observed, it is conceivable to suggest that the release of hydroxyl may be maintained for a long time in the Calen paste. Superficial necrosis areas may be explained due to high pH provided by medications that induces the rupture of cellular membranes and their content leak out, culminating in an inflammatory reaction. However, the cellular damage promoted by these medications may be restricted to tissue area in close juxtaposition to the medication. The alkaline pH promotes vascular proliferation and stimulates the recruitment the macrophages, which migrate to these sites, phagocytizing cell debris and extracellular matrix components. Moreover, superficial necrosis stimulates proliferation and differentiation of mesenchymal cells culminating with collagen formation. Calci-
by mast cells. Mast cells contain IL-10 receptors, and, via IL-10, release several inflammatory mediators, which mediate the immune and inflammatory responses and participate in the tissue repair and remodelling. The accentuated number of mast cells in the capsules around a reparative calcium silicate-based biomaterial, Biodentine (Septodont, Saint-Maur-des-Fossées, France), was associated with fibroblasts proliferation and, consequently, with the collagen formation supporting the concept that mast cells are involved in the connective tissue repair. Moreover, there is evidence that IL-10 inhibits IL-6 production by mast cells in response to inflammation and bacterial infection. Thus, our findings taken together indicate that the increase in the IL-10 may inhibit the immunoenexpression of IL-6 in the capsules mitigating the inflammatory reaction promoted by bioceramic and calcium hydroxide intracanal medications implanted in the subcutaneous tissues.

No study evaluating the biological in vivo behavior of the Bio-C Temp was found in the literature. Our findings indicate that, in the initial period, bioceramic medication induced an intense inflammatory reaction, which gradually reduced over time. Thus, at 60 days, the capsules around Bio-C Temp specimens showed bundles of collagen fibers surrounding the material particles, pointing to a connective tissue reorganization, and, therefore, indicating that this bioceramic medication is biocompatible. The biocompatibility of tricalcium silicate-based materials seems to be due to the stable chemical comportment of the calcium silicate in biological environment. Therefore, it is expected that Bio-C Temp, when in contact with periapical tissues, may induce the tissue repair. Although subcutaneous implantation in rats is a methodology recommended by ISO 10993 to assess the biocompatibility of dental materials, it is important to emphasize that the intracanal medication has contact with infected and/or inflamed periradicular tissues. Moreover, the periodontal microenvironment contains, differently from subcutaneous connective tissue, other cell types besides fibroblasts, such as cementoblasts, osteoblasts and osteoclasts. Despite its biocompatibility, it is still unclear whether Bio-C Temp has antimicrobial efficacy and whether possible residues of this medication might interfere in the properties of endodontic sealers. Therefore, further studies are necessary to confirm the safety and viability of this bioceramic intracanal medication in clinical practice.

In conclusion, serum GOT and GPT levels suggest that bioceramic and calcium hydroxide-based intracanal medications had no hepatotoxicity effect. Bio-C Temp caused initial tissue damage that was quickly suppressed in comparison to those caused by calcium hydroxide-based paste, favouring the repair of connective tissue indicating, therefore, that this bioceramic material is biocompatible.

Materials and methods

Experiment design. The present research protocol was approved by the Ethical Committee for Animal Research of Araquara Dental School (FOAr-Araquara, UNESP, São Paulo, Brazil; CEUA # 22/2018). Sixty adult male Holtzman rats (Rattus norvegicus albinus) weighing 220–250 g were used. The rats were maintained in polyethylene cages under 12 h light/12 h dark cycle at controlled temperature (23 ± 2 °C) and humidity (55 ± 10%), with water and food provided ad libitum. The study was carried out in accordance with the US National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23, 1996). The experiment and analyses method were conducted in accordance with ARRIVE guidelines 2.0 (Animal Research: Reporting of In Vivo Experiments).

Sixty rats were randomly distributed into three groups containing 20 animals each (Fig. 7): BIO (Bio-C TEMP Group, Angelus, Londrina, Brazil); CAL (Calen Group, SS. White Art. Dent. Ltda, RJ, Brazil) and CG (control group, empty polyethylene tubes). Each cage was identified according to the group and period. The sample size for this study was calculated based in previous studies. The size sample was calculated considering an alpha error of 0.05 to recognize a significant difference and 90% test power for detection of 50% difference among experimental groups and CG. Thus, a sample of 5 rats per group in each time point was required, totaling twenty animals per group.

The animals were anaesthetized with ketamine hydrochloride (80 mg/kg of body weight) and xylazine hydrochloride (8 mg/kg of body weight) by intraperitoneal route. After shaved and disinfection with 5% iodine solution, a 2.0 cm-long incision was made in a head-to-tail orientation using a no. 15 scalpel (Fibra Cirúrgica, Joinville,SC, Brazil). The polyethylene tube (Embramed Indústria e Comércio Ltda, São Paulo, São Paulo, Brazil) with 10.0 mm length and 1.6 mm diameter, previously sterilized with ethylene oxide, were implanted into the subcutaneous tissue. In each animal, two polyethylene tubes of the same group were implanted for 7, 15, 30 and 60 days (Fig. 7).

Serum hepatic enzymes level. To evaluate whether intracanal medications cause changes in the hepatic enzymes (GOT and GPT), the blood samples were collected through cardiac puncture with BD Vacutainer Blood Collection Tubes (SSTII Plus, BD Biosciences) at 7 and 60 days (Fig. 7). After clot formation, the blood was centrifuged (Excelsa II 206 BL; Fanem Ltda., Guarulhos, SP, Brazil) at 3500 rpm for 10 min and the serum was stored at -20 °C. The GOT and GPT serum concentrations were determined using the AST (aspartate aminotransferase) and ALT (Alanine Aminotransferase), respectively, by chemiluminescence immunoassay kits (Beckman Coulter, CAR, USA). Concentrations were measured using a multiparametric automatic analyzer (Cobas INTEGRA® 400 Plus; Roche Diagnóstica Brasil Ltda., São Paulo, SP, Brazil). The analyses were performed at São Lucas Clinical and Microbiological Laboratory. The experiments were carried out in duplicate and the averages were calculated.

Histological processing of samples. The tissue reaction promoted by intracanal medications was carried out in all groups at 7, 15, 30, and 60 days. The animals were euthanized with overdose of ketamine and xylazine and, subsequently, the specimens containing the implants surrounded by tissues were removed and immersed in 4% formaldehyde (freshly prepared from paraformaldehyde) buffered at pH 7.2 with 0.1 M sodium phosphate.

Scientific Reports | (2022) 12:2788 | https://doi.org/10.1038/s41598-022-06545-5
After 48 h, the specimens were dehydrated with ethanol graded concentrations, treated with xylene, and embedded in paraffin. In each specimen, forty serial longitudinal sections (6 µm thick) were obtained and adhered to glass slides. Three non-serial sections were stained with Carazzi’s hematoxylin and eosin (HE) for morphological analysis of the capsules, and to estimate the capsule thickness and the numerical density of inflammatory cells. Three non-serial sections were subjected to the picrosirius-red to estimate the collagen content. Other non-serial sections were adhered to slides previously treated with silane 4% (Sigma-Aldrich) and submitted to the immunohistochemistry reactions for detection of interleukin-6 (IL-6) and IL-10 (Fig. 7).

The histological description and quantitative data were obtained using a digital camera (DP-71, Olympus, Tokyo, Japan) attached to a light microscope (Olympus BX-51, Tokyo, Japan) and an image analysis system (Image-Pro Express 6.0, Olympus). The analyses were conducted by one calibrated and blinded examiner.

**Numerical density of inflammatory cells.** The number of inflammatory cells was obtained from three non-serial sections of each implant. In each section, an image of the central portion of capsule in close juxtaposition to the opening of implanted tube was captured at ×695 magnification (objective lens: ×40). In this standardized field (0.09 mm²), the number of inflammatory cells (neutrophils, lymphocytes, plasma cells, and macrophages) was computed using the image analysis system. Thus, the number of inflammatory cells per mil-

---

**Figure 7.** Flowchart of experimental design with total number of animals, number of animals per group and methodological analyses performed in the study.
limet square of capsule was obtained dividing the total number of inflammatory cells by the total standardized field of capsule\textsuperscript{3,24,27,33,45}. 

**Capsule thickness.** For each specimen, three HE-stained non-serial sections were used, totalling 15 sections per group in each period. To estimate the capsule thickness, an image at × 40 magnification was captured (objective lens: × 4); the measurement was made from the capsule surface to the adjacent tissues (in micrometers). In each specimen, the mean value of capsule thickness was calculated from the three sections analyzed\textsuperscript{3,24,45}. 

**Immunohistochemical detection of IL-6 and IL-10.** For the detection of interleukin-6 and interleukin-10, mouse monoclonal anti-IL-6 antibody (Abcam Inc., Cambridge, MA, USA; code: ab 9324) and mouse monoclonal anti-IL-10 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA; code SC-8438) were used. After deparaffinization and hydration, the slides were immersed in 0.001 M sodium citrate buffer (pH 6.0) and subjected to microwave for 20 min at 96–98 °C. After cooling-off, the slides were washed in 0.01 M sodium phosphate buffer (PBS) for 15 min. For inactivation of endogenous peroxidase, the sections were immersed for 30 min in 5% aqueous hydrogen peroxide. After washing in PBS, the sections were incubated for 20 min with 2% bovine serum albumin (Sigma-Aldrich Co., Saint Louis, Missouri, USA) at room temperature. Afterwards, the sections were incubated with anti-IL-6 antibody (diluted at 1:400) or anti-IL-10 antibody (diluted at 1:100) in a humid chamber at 4 °C for 16 h. After washings with PBS, the sections were incubated for 60 min with the labeled StreptAvidin-Biotin kit (Universal Dako LSAB, Dako Inc., Carpinteria, CA, USA; K0675) at room temperature. Peroxidase activity was revealed by 3,3′-diaminobenzidine chromogen (DAB substrate, Vector Laboratories, Burlingame, CA, USA) for 3 min. The sections were stained with Carazzi’s hematoxylin. As a negative control, the sections were incubated with non-immune serum. Subsequently, the quantification of immunostained cells was performed. 

The number of IL6- and IL10-immunolabelled cells was estimated in the capsules of five specimens of each group/period. In each section, a standardized area (0.09 mm\textsuperscript{2}) was captured at × 695 magnification (objective lens: × 40). Using the image analysis system, the number of immunolabelled cells (brown-yellow color) was computed\textsuperscript{3,24,27,33,45}. 

**Measurement of birefringent collagen.** The amount of collagen was estimated in three non-serial sections stained with picrosirius-red and analyzed under polarized illumination. In each section, the birefringent collagen was measured in a standardized field (0.09 mm\textsuperscript{2}) of the capsule at × 695 magnification (objective lens: × 40). All images were captured with standardized light intensity, field diaphragm aperture, condenser diaphragm and exposure time. The amount of birefringent collagen was performed using the ImageJ software, which provided the number of pixels of each color frequency (red, orange, yellow and green) occupied in the total pixel value of the captured images\textsuperscript{3,33,45}. 

**Statistical analysis.** The GraphPad Prism 6.01 program (GraphPad Software, Inc., La Jolla, CA, USA) was used, and the data were submitted to two-way ANOVA analysis of variance, followed by the Tukey test (p ≤ 0.05). All data were presented as mean ± standard deviation.

**References**

1. Siqueira, J. F. Jr. & Rôças, I. N. Clinical implications and microbiology of bacterial persistence after treatment procedures. *J. Endod.* **34**, 1291–1301 (2008).

2. Vera, J. et al. One- versus two-visit endodontic treatment of teeth with apical periodontitis: A histobacteriologic study. *J. Endod.* **38**, 1040–1052 (2012).

3. Chong, B. S. & Pitt Ford, T. R. The role of intracanal medication in root canal treatment. *Int. Endod. J.* **25**, 97–106 (1992).

4. Hasselgren, G., Olsson, B. & Cvek, M. Effects of calcium hydroxide and sodium hypochlorite on the dissolution of necrotic porcine muscle tissue. *J. Endod.* **14**, 125–127 (1998).

5. Mizuno, M. & Banzai, Y. Calcium ion release from calcium hydroxide stimulated fibronectin gene expression in dental pulp cells and the differentiation of dental pulp cells to mineralized tissue forming cells by fibronectin. *Int. Endod. J.* **41**, 933–938 (2008).

6. Silva, L. A. et al. Histopathological evaluation of root canal filling materials for primary teeth. *Braz. Dent. J.* **21**, 38–45 (2010).

7. Alaçam, T., Görgül, G. & Omürlü, H. Evaluation of diagnostic radiopaque contrast materials used with calcium hydroxide. *J. Endod.* **16**, 365–368 (1990).

8. Fava, L. R. & Saunders, W. P. Calcium hydroxide pastes: Classification and clinical indications. *Int. Endod. J.* **32**, 257–282 (1999).

9. Andolfatto, C. et al. Biocompatibility of intracanal medications based on calcium hydroxide. *ISRN Dent.* **2012**, 904963 (2012).

10. Hawkins, J. I., Torabinejad, M., Li, Y. & Retamozo, B. Effect of three calcium hydroxide formulations on fracture resistance of dentin over time. *Dent. Traumatol.* **31**, 380–384 (2015).

11. Kahler, S. L., Shetty, S., Andreasen, F. M. & Kahler, B. The effect of long-term dressing with calcium hydroxide on the fracture susceptibility of teeth. *J. Endod.* **44**, 464–469 (2018).

12. Dudeja, C., Tanjea, S., Kumari, M. & Singh, N. An in vitro comparison of effect on fracture strength, pH and calcium ion diffusion from various bioceramic sealers when used for repair of simulated root resorption defects. *J. Conserv. Dent.* **18**, 279–283 (2015).

13. Espaladori, M. C. et al. Characterization and hydration kinetics of tricalcium silicate cement for use as a dental biomaterial. *Int. Endod. J.* **38**, 1291–1301 (2005).

14. Prati, C. & Gandolfi, M. G. Calcium silicate bioactive cements: Biological perspectives and clinical applications. *Dent. Mater.* **31**, 351–370 (2015).

15. Camilleri, J. Characterization and hydration kinetics of tricalcium silicate cement for use as a dental biomaterial. *Dent. Mater.* **27**, 836–844 (2011).

16. Giacomin, C. M., Wealeeams, J. A., Kuhn, N. & Diogenes, A. Comparative biocompatibility and osteogenic potential of two bioceramic sealers. *J. Endod.* **45**, 51–56 (2019).
17. Camps, J., Jeanneau, C., El Ayachi, L., Laurent, P. & About, I. Bioactivity of a calcium silicate-based endodontic cement (BioRoot RCS): Interactions with human periodontal ligament cells in vitro. *J. Endod.* **41**, 1469–1473 (2015).

18. Villa, N. *et al.* A new calcium silicate-based root canal dressing: Physical and chemical properties, cytotoxicity and dentinal tubule penetration. *Braz. Dent. J.* **31**, 598–604 (2020).

19. Guerreiro, J. C. M. *et al.* Antibacterial activity, cytocompatibility and effect of Bio-C Temp bioceramic intracanal medicament on osteoblast biology. *Int. Endod. J.* **54**, 1155–1165 (2021).

20. Angelus Indústria de Produtos Odontológicos S/A Bio-C Temp brochure. *Angelus Indústria de Produtos Odontológicos S/A* http://www.angelusdental.com/img/arquivos/2833_10502833_011102019_bio_c_temp_bula_fechado_pdf (2021).

21. Oliveira, L. V. *et al.* A laboratory evaluation of cell viability, radiopacity and tooth discoloration induced by regenerative endodontic materials. *Int. Endod. J.* **53**, 1140–1152 (2020).

22. Silva, G. F., Tanomaru-Filho, M., Bernardi, M. I., Guerreiro-Tanomaru, J. M. & Cerri, P. S. Niobium pentoxide as radiopacifying agent of calcium silicate-based material: Evaluation of physicochemical and biological properties. *Clin. Oral Investig.* **19**, 2015–2025 (2015).

23. Saravia, J. A. *et al.* Reduced interleukin-6 immunoexpression and birefringent collagen formation indicate that MTA Plus and MTA Fillapex are biocompatible. *Biomed. Mater.* **13**, 035002 (2018).

24. Delfino, M. M., Guerreiro-Tanomaru, J. M., Tanomaru-Filho, M., Sasso-Cerri, E. & Cerri, P. S. Immunoinflammatory response and bioactive potential of GuttaFlow bioseal and MTA Fillapex in the rat subcutaneous tissue. *Sci. Rep.* **10**, 7173 (2020).

25. Hoshino, R. A. *et al.* Physical properties, antimicrobial activity and in vivo tissue response to Apex Plus. *Materials (Basel)* **13**, 1171 (2020).

26. Viola, N. V. *et al.* Biocompatibility of an experimental MTA sealer implanted in the rat subcutaneous: quantitative and immunohistochemical evaluation. *J. Biomed. Mater. Res. B Appl. Biomater.* **100**, 1773–1781 (2012).

27. da Fonseca, T. S. *et al.* In vivo evaluation of the inflammatory response and IL-6 immunoexpression promoted by Biodentine and MTA Angelus. *Int. Endod. J.* **49**, 145–153 (2016).

28. Delfino, M. M. *et al.* Comparison of Bio-C Pulpo and MTA repair HP with white MTA: Effect on liver parameters and evaluation of biocompatibility and bioactivity in rats. *Int. Endod. J.* **54**, 1597–1613 (2021).

29. Mahmud, Z., Bachar, S. & Qais, N. Antioxidant and hepatoprotective activities of ethanolic extracts of leaves of *Premna esculenta* roth. against carbon tetrachloride-induced liver damage in rats. *J. Young Pharm.* **4**, 228–234 (2012).

30. Ozer, I., Ratner, M., Shaw, M., Bailey, W. & Schomaker, S. The current state of serum biomarkers of hepatotoxicity. *Toxicology* **245**, 194–205 (2008).

31. Dhupal, M. *et al.* Immunoexpression of titanium dioxide nanoparticles via simultaneous induction of apoptosis and multiple toll-like receptors signaling through ROS-dependent SAPK/JNK and p38 MAPK activation. *Int. J. Nanomed.* **13**, 6735–6750 (2018).

32. Bakopoulou, A., Papadopoulou, T. & Garelis, P. Molecular toxicology of substances released from resin-based dental restorative materials. *Int. J. Mol. Sci.* **10**, 3861–3899 (2009).

33. Silva, G. F. *et al.* Microparticulated and nanoparticulated zirconium oxide added to calcium silicate cement: Evaluation of physicochemical and biological properties. *J. Biomed. Mater. Res. A* **102**, 4336–4345 (2014).

34. Silva, G. F. *et al.* Zirconium oxide and niobium oxide used as radiopacifiers in a calcium silicate-based material stimulate fibroblast proliferation and collagen formation. *Int. Endod. J.* **50**, e95–e108 (2017).

35. Leonardo, M. R., Bezerra da Silva, L. A., Utrilla, L. S., Leonardo, R. T. & Consolaro, A. Effect of intracanal dressings on repair and apical bridging of teeth with incomplete root formation. *Endod. Dent. Traumatol.* **9**, 25–30 (1993).

36. Holland, R., Pinheiro, C. E., de Mello, W., Nery, M. J. & de Souza, V. Histochemical analysis of the dogs' dental pulp after pulp capping with calcium, barium, and strontium hydroxides. *J. Endod.* **8**, 444–447 (1982).

37. Midena, R. Z. *et al.* Analysis of the reaction of subcutaneous tissues in rats and the antimicrobial activity of calcium hydroxide paste used in association with different substances. *J. Appl. Oral Sci.* **23**, 508–514 (2015).

38. da Silva, G. F. *et al.* Effect of association of non-steroidal anti-inflammatory and antibiotic agents with calcium hydroxide pastes on their cytotoxicity and biocompatibility. *Clin. Oral Investig.* **24**, 757–763 (2020).

39. Schröder, U. Effects of calcium hydroxide-containing pulp-capping agents on pulp cell migration, proliferation, and differentiation. *J. Dent. Res.* **64**, 541–548 (1985).

40. Estrella, C., Sydney, G. B., Bammann, L. L. & Felippe Júnior, O. Mechanism of action of calcium and hydroxyl ions of calcium hydroxide on tissue and bacteria. *Braz. Dent. J.* **6**, 85–90 (1995).

41. Mohammadi, Z. & Dummer, P. M. Properties and applications of calcium hydroxide in endodontics and dental traumatology. *Int. Endod. J.* **44**, 697–730 (2011).

42. Junqueira, L. C., Cossermelli, W. & Brentani, R. Differential staining of collagens type I, II and III by Sirius Red and polarization microscopy. *Arch. Histol. Exp.* **41**, 267–274 (1978).

43. Cuttle, L. *et al.* Collagen in the scarless fetal skin wound: Detection with picrosirius-polarization. *Wound Repair Regen.* **13**, 198–204 (2005).

44. da Fonseca, T. S. *et al.* Mast cells and immunoexpression of FGF-1 and Ki-67 in rat subcutaneous tissue following the implantation of Biocerentine and MTA Angelus. *Int. Endod. J.* **52**, 54–67 (2019).

45. Silva, E. C. A. *et al.* Evaluation of the biological properties of two experimental calcium silicate sealers: An in vivo study in rats. *Int. Endod. J.* **54**, 100–111 (2021).

46. Economides, N. *et al.* Experimental study of the biocompatibility of four root canal sealers and their influence on the zinc and calcium content of several tissues. *J. Endod.* **21**, 122–127 (1995).

47. Cosme-Silva, L. *et al.* Biocompatibility and biominerabilization ability of Bio-C Pulpjecto. A histological and immunohistochemical study. *Int. J. Paediatr. Dent.* **29**, 352–360 (2019).

48. de Oliveira, P. A., de Pizzol-Júnior, J. P., Longhini, R., Sasso-Cerri, E. & Cerri, P. S. Cimetidine reduces interleukin-6, matrix metalloproteinases-1 and -9 immunoexpression in the gingival mucosa of rat molars with induced periodontal disease. *J. Periodontol.* **88**, 100–111 (2017).

49. Blank, U. *et al.* Vesicular trafficking and signaling for cytokine and chemokine secretion in mast cells. *Front. Immunol.* **5**, 453 (2014).

50. Marshall, J. S., Leal-Berumen, I., Nielsen, L., Gilbetic, M. & Jordana, M. Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat periodontal mast cells. *J. Clin. Investig.* **97**, 1122–1128 (1996).

51. Candeiro, G. T., Correia, F. C., Duarte, M. A., Ribeiro-Siqueira, D. C. & Gavini, G. Evaluation of radioopacity, pH, release of calcium ions, and flow of a bioceramic root canal sealer. *J. Endod.* **38**, 842–845 (2012).

52. International Organization for Standardization. Biological evaluation of medical devices. Part 6: tests for local effects after implantation. *ISO* 10993–6 (2016).

Acknowledgements

This work was carried out with the financial support from the São Paulo State Research Foundation (FAPESP: 2018/16848-2), National Council for Scientific and Technological Development (CNPq) and CAPES (code 001).
Author contributions
C.S.L. contributed to the conceptualization, experiment, methodology, analysis, writing, editing, and critical review of the article. M.M.D. contributed to the experiment, methodology, analysis, writing, and critical review of the article. M.T.-F. contributed to the conceptualization, and critical review of the article. E.S.-C. contributed to the experiment, methodology, analysis, writing, and critical review of the article. J.M.G.-T. contributed to the experiment, analysis, writing, and critical review of the article. P.S.C. contributed to the conceptualization, funding acquisition, methodology, supervision, project administration, writing, and critical review of the article. All authors reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to P.S.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022